| ²é¿´: 852 | »Ø¸´: 0 | |||
ÉúÎïÇ°ÑØÑо¿ÊÒгæ (СÓÐÃûÆø)
|
[½»Á÷]
ϸ°û½¹ÍöºÍ·Ö×Ó»úÖÆ
|
|
ϸ°ûËÀÍö¿É·ÖΪ·ÇÊܿصÄÒâÍâÐÔϸ°ûËÀÍö£¨accidental cell death£¬ACD£©ºÍ¿ÉÊܿصĵ÷½ÚÐÔϸ°ûËÀÍö£¨regulated cell death£¬RCD£©£¬RCDÔÚÉúÀíÌõ¼þÏÂÒ²³ÆÎª³ÌÐòÐÔϸ°ûËÀÍö£¨programmed cell death£¬PCD£©¡£ PCDÊÇϸ°ûµÄÒ»ÖÖ×Ôɱ»úÖÆ£¬ËüÄܹ»Çå³ý»úÌåÎÞÓûò°©±äµÄϸ°û£¬¶ÔÓÚά³ÖÈËÌåÄÚ»·¾³ÎÈ̬¡¢·¢ÓýºÍÉú´æÓÐÖØÒªµÄÒâÒ壬¶øPCDµÄÒì³£ÍùÍù°éËæ×ż²²¡µÄ·¢Éú¡£Ä¿Ç°ÒÑÖªµÄPCDÓÐϸ°ûµòÍö¡¢»µËÀÐÔµòÍöºÍϸ°û½¹ÍöµÈ¡£ Óëϸ°ûµòÍöºÍ»µËÀÐÔµòÍöÏà±È½Ï£¬Ï¸°û½¹Íö·¢Éú¸ü¿ì¡¢¸ü¾çÁÒ£¬Í¬Ê±ÏòÍâÊÍ·ÅÖÚ¶à´ÙÑ×Òò×Ó¡£ 01 ϸ°û½¹Íö¡¢Ï¸°ûµòÍöºÍ»µËÀÐÔµòÍöÖ®¼äµÄÒìͬµã ϸ°ûµòÍö¹ã·º²ÎÓëÅßÌ¥·¢Éú¡¢Ë¥ÀÏ¡¢¸ÐȾºÍÖ×ÁöÏûÍ˵ȶàÖÖÉúÎïѧ¹ý³Ì¡£Ï¸°ûµòÍöµÄÖ÷ÒªÐÎÌ¬Ñ§ÌØÕ÷°üÀ¨Ï¸°ûĤÆðÅÝ¡¢Ï¸°ûÖåËõ¡¢È¾É«ÖÊÄý¾Û¡¢ºËËéÁѺ͵òÍöСÌåµÄÐγɡ£ Óë±£ÁôÍêÕûϸ°ûĤµÄµòÍöϸ°û²»Í¬£¬»µËÀÐÔµòÍöºÍϸ°û½¹Íö¾ùÓµÓи÷×ÔµÄÖ´Ðе°°×ÖÊ£¬·Ö±ðΪ»ìºÏÆ×ϵµ°°×¼¤Ã¸Ñù½á¹¹Óò£¨mixed lineage kinase domain-like protein£¬MLKL£©¼°Gasdermin D£¨GSDMD£©£¬ÇÒ¾ù¿ÉÒ×λÖÁÖÊĤÒýÆð´©¿×¡£Òò´Ë£¬ÔÚ½¹ÍöºÍ»µËÀÐÔµòÍöϸ°ûÖÐͨ³£¿ÉÒԹ۲쵽ϸ°ûµÄÖ×ÕͺÍϸ°ûÄ¤ÆÆÁÑ¡£Óëϸ°ûµòÍöÒ»Ö£¬½¹Íöϸ°û±íÏÖΪDNA¶ÏÁѺÍȾɫÖÊÄý¾Û£¬µ«Ï¸°ûºËͨ³£±£³ÖÍêÕû£¬ÕâÓëϸ°ûµòÍöºÍ»µËÀÐÔµòÍöÖй۲쵽µÄϸ°ûºËÆÆÁÑÏÖÏó²»Í¬¡£ÓÉÓÚϸ°ûĤÊÜËð£¬ÖÂʹһЩÑ×Ö¢Òò×ÓºÍËðÉËÏà¹Ø·Ö×Óģʽ£¨damage associated molecular patterns£¬DAMPs£©·Ö×Ó´Ó½¹ÍöºÍ»µËÀÐÔµòÍöϸ°ûÖÐÊͷųöÀ´£¬ËæºóÒý·¢Ç¿ÁÒµÄÑ×Ö¢·´Ó¦¡£ 01ϸ°ûµòÍö±»ÈÏΪÊÇÒ»ÖÖ·ÇÑ×Ö¢¹ý³Ì£¬ÔÚϸ°ûµòÍöÖÐÒ²´æÔÚÏÙÜÕÈýÁ×Ëᣨadenosine triphosphate£¬ ATP£© ºÍ¸ßÇ¨ÒÆÂÊ×åµ°°×B1£¨high mobility group protein 1£¬HMGB1£©µÈÌØ¶¨DAMPsµÄÊÍ·Å¡£ÔÚ·Ö×Ó»úÖÆ·½Ã棬ë×Ììµ°°×ø£¨caspase£©¹ã·º²ÎÓë3ÖÖPCD¡£ 02 ϸ°û½¹Íö´«Í³É϶¨ÒåΪcaspase-1½éµ¼µÄϸ°ûËÀÍö£¬µ«Ñо¿ÏÔʾÆäËûcaspase£¬Èçcaspase-4¡¢caspase-5¡¢caspase-11¾ùÄܹ»½éµ¼²¢Í¨¹ýGSDMDÖ´ÐÐϸ°û½¹Íö¡£ 03 ¶øµòÍö;¾¶ÔòÓÉÁíÒ»×écaspase£¬Èçcaspase-2¡¢caspase-3¡¢caspase-6¡¢caspase-7¡¢caspase-8¡¢caspase-9¡¢caspase-10²ÎÓëÆô¶¯ºÍÖ´ÐС£»µËÀÐÔµòÍö²»Í¬ÓÚϸ°û½¹ÍöºÍµòÍö£¬²¢²»ÒÀÀµÓÚcaspase »îÐÔ£¬¶øÊÇÓÉÊÜÌåÏ໥×÷Óõ°°×¼¤Ã¸£¨receptor-interacting protein kinase£¬RIP£©1/RIP3½éµ¼²¢Í¨¹ýMLKLÖ´ÐÐϸ°ûËÀÍö¡£¾¡¹Ü¶ÔÓÚ»µËÀÐÔµòÍöÀ´ËµcaspaseÊÇ¿ÉÓпÉÎ޵쬵«caspase-8µÄʧ»î»òȱʧȴÊÇ»µËÀÐÔµòÍö¼¤»îµÄÏȾöÌõ¼þ¡£ ¾ßÌåµÄ²»Í¬µã¼û±í1 DAMPs£ºËðÉËÏà¹Ø·Ö×Óģʽ£»ATP£ºÏÙÜÕÈýÁ×Ë᣻HMGB1£º¸ßÇ¨ÒÆÂÊ×åµ°°×B1£»caspase£ºë×Ììµ°°×ø£»GSDMD£ºGasdermin D£»RIP£ºÊÜÌåÏ໥×÷Óõ°°×¼¤Ã¸£»MLKL£º»ìºÏÆ×ϵµ°°×¼¤Ã¸Ñù½á¹¹Óò¡£ 02 ϸ°û½¹ÍöµÄ·Ö×Ó»úÖÆ£¨¾µäͨ·£© ͼ1 ϸ°û½¹ÍöÐźÅͨ· ϸ°û½¹ÍöÐèÒªÒÀÀµcaspase-1½øÐм¤»î£¬ÆäÖÐÑ×֢СÌåÆðµ½ÖØÒª×÷Óá£Ñ×֢СÌåͨ³£ÓÉģʽʶ±ðÊÜÌ壨pattern recognition receptors£¬PRR£©¡¢caspase-1ǰÌåÒÔ¼°ÔÚÌØ¶¨Çé¿öÏÂÁ¬½ÓÕâЩµ°°×ÖʵÄÏνӵ°°××é³É¡£ ÔÚÑ×֢СÌåÖÐ×î³£¼ûµÄPRR°üÀ¨NODÑùÊÜÌ壨NOD-like receptors£¬NLRs£©¡¢ºËÜÕËá½áºÏ¹Ñ¾Û»¯½á¹¹ÓòÑùÊÜÌåµ°°×£¨nucleotide-binding, leucine-rich repeat pyrin domain containing protein£¬NLRP£©1¡¢NLRP3¡¢NLRC4ºÍºÚÉ«ËØÁöȱ·¦Òò×Ó2 £¨absent in melanoma 2£¬AIM2£©£¬ËüÃÇ¿ÉÒÔ±»¸÷ÖÖÄÚÔ´ÐÔ»òÍâÔ´ÐԴ̼¤¼¤»î¡£ NLRP1ʶ±ðÌ¿¾ÒÑ¿æß¸Ë¾úÖÂËÀ¶¾ËØÓÕµ¼Ï¸°û½¹Íö£¬NLRC4¶Ôϸ¾úµ°°×ÖÊ·´Ó¦Ç¿ÁÒ£¬¶øAIM2Ö÷ÒªÓÉϸ¾ú»ò²¡¶¾¸ÐȾϸ°ûÖеÄË«Á´DNA¼¤»î¡£×÷ΪÑо¿×îΪ¹ã·ºµÄPRR£¬NLRP3ÊܶàÖÖÒòËØ´Ì¼¤£¬°üÀ¨Ï¸¾ú¶¾ËØ¡¢²¡¶¾Ë«Á´RNA¡¢ATP¡¢»îÐÔÑõÒÔ¼°ÄÚÔ´ÐÔËðÉËÐźŵȡ£ ¼¤»îºóµÄNLRP3Óëcaspase-1ǰÌåÒÔ¼°µòÍöÏà¹Ø°ßµãÑùµ°°×ÐγÉÑ×֢СÌ壬½øÒ»²½Æô¶¯Ï¸°û½¹Íö¡£Ñо¿±íÃ÷GSDMDÊǵ÷¿ØÏ¸°û½¹ÍöµÄÖØÒªµ×Îͨ¹ýÑ×֢СÌåʵÏֻµÄcaspase-1Ö±½ÓÇиîGSDMDµÄN¶ËÐòÁУ¬Ê¹Æä³ÉΪ¾ßÓгɿ׻îÐÔµÄGSDMD-NT£¬GSDMD-NT×ªÒÆµ½Ï¸°ûĤÐγÉÄÚ¾¶10~14 nmµÄ·ÇÑ¡ÔñÐÔ¿×£¬´¥·¢Ï¸°ûµÄÖ×ÕͺÍϸ°û½¹Íö¡£ »î»¯µÄcaspase-1Ò²¿É´Ù½ø°×ϸ°û½éËØ£¨interleukin£¬IL£©-1¦ÂǰÌåºÍIL-18ǰÌåµ°°×ÖÊË®½â£¬×ª»¯ÎªÆäÉúÎï»îÐÔÐÎʽ£¬Ëæºó½èÖúGSDMDÉú³ÉµÄ¡°¿×µÀ¡±ÏòÍâÊÍ·Å£¬ÔöÇ¿ÁË»úÌåµÄÑ×Ö¢·´Ó¦ ·¢×ÔСľ³æIOS¿Í»§¶Ë |
» ²ÂÄãϲ»¶
²ÄÁÏ¿¼Ñе÷¼Á
ÒѾÓÐ25È˻ظ´
²ÄÁϹ¤³Ì281»¹Óе÷¼Á»ú»áÂð
ÒѾÓÐ11È˻ظ´
303Çóµ÷¼Á
ÒѾÓÐ12È˻ظ´
290µ÷¼ÁÉúÎï0860
ÒѾÓÐ14È˻ظ´
ũѧ0904 312Çóµ÷¼Á
ÒѾÓÐ3È˻ظ´
Çóµ÷¼Á
ÒѾÓÐ7È˻ظ´
11408¡£358Çóµ÷¼Á
ÒѾÓÐ3È˻ظ´
ÇóÖúµ÷¼Á£¬¿çµ÷
ÒѾÓÐ8È˻ظ´
271Çóµ÷¼Á
ÒѾÓÐ8È˻ظ´
Ò»Ö¾Ô¸Ïôó0856£¬306Çóµ÷¼Á
ÒѾÓÐ10È˻ظ´













»Ø¸´´ËÂ¥